Alaunos Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Alaunos Therapeutics
TCRT Stock  USD 3.23  0.29  8.24%   
Analyzing historical trends in various income statement and balance sheet accounts from Alaunos Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Alaunos Therapeutics' valuation are summarized below:
Gross Profit
-910 K
Market Capitalization
7.2 M
Enterprise Value Revenue
191.1345
Revenue
6 K
Earnings Share
(2.30)
There are currently one hundred twenty fundamental signals for Alaunos Therapeutics that can be evaluated and compared over time across rivals. All traders should validate Alaunos Therapeutics' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 2.9 M in 2025. Enterprise Value is likely to drop to about 1.9 M in 2025

Alaunos Therapeutics Total Revenue

9,500

Check Alaunos Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Alaunos Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.9 K, Selling And Marketing Expenses of 4.1 M or Total Revenue of 9.5 K, as well as many indicators such as Price To Sales Ratio of 291, Dividend Yield of 0.0294 or PTB Ratio of 1.56. Alaunos financial statements analysis is a perfect complement when working with Alaunos Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Alaunos Stock
Check out the analysis of Alaunos Therapeutics Correlation against competitors.
For more information on how to buy Alaunos Stock please use our How to Invest in Alaunos Therapeutics guide.

Alaunos Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets2.6 M2.8 M74.9 M
Pretty Stable
Short and Long Term Debt Total12.6 M23.1 M8.2 M
Slightly volatile
Cash1 M1.1 M60.1 M
Slightly volatile
Other Assets0.860.96.7 M
Slightly volatile
Cash And Short Term Investments1 M1.1 M60.1 M
Slightly volatile
Net Receivables4.8 K5 K743.6 K
Pretty Stable
Common Stock Shares Outstanding1.7 M1.6 M1 M
Slightly volatile
Liabilities And Stockholders Equity2.6 M2.8 M74.9 M
Pretty Stable
Other Current Assets1.6 M1.7 M10.9 M
Very volatile
Other Stockholder Equity968.6 M922.5 M632.2 M
Slightly volatile
Total Liabilities657.4 K692 K41.9 M
Pretty Stable
Total Current Assets2.6 M2.8 M69.7 M
Slightly volatile
Intangible Assets582437519
Slightly volatile
Other Current Liabilities167.2 K176 K7.1 M
Slightly volatile
Total Current Liabilities657.4 K692 K11.8 M
Pretty Stable
Accounts Payable490.2 K516 K1.2 M
Pretty Stable
Common Stock1.9 K2 K119.8 K
Very volatile
Short Term Investments1.2 M1.4 M1.5 M
Slightly volatile
Current Deferred Revenue14.2 K14.9 K1.5 M
Pretty Stable
Property Plant Equipment8.1 M9.7 M4.9 M
Slightly volatile
Net Invested Capital2 M2.1 M71.1 M
Slightly volatile
Capital Stock1.9 K2 K145.1 K
Slightly volatile
Net Working Capital2 M2.1 M61.3 M
Slightly volatile
Property Plant And Equipment Gross12.8 K13.5 K8.3 M
Pretty Stable
Short Term Debt21.6 M20.6 M6 M
Slightly volatile
Long Term Debt13 M14.6 M15.9 M
Slightly volatile
Short and Long Term Debt13.5 M19.3 M10 M
Slightly volatile
Common Stock Total Equity192 K216 K235.5 K
Slightly volatile
Capital Surpluse735.2 M827 M901.7 M
Slightly volatile
Inventory11.2 M12.5 M13.7 M
Slightly volatile

Alaunos Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.9 K2 K821.7 K
Slightly volatile
Selling And Marketing Expenses4.1 M2.7 M2.3 M
Slightly volatile
Other Operating Expenses4.6 M4.8 M61.7 M
Slightly volatile
Total Operating Expenses4.6 M4.8 M61.3 M
Slightly volatile
Research Development343.9 K362 K46.8 M
Slightly volatile
Selling General Administrative4.2 M4.5 M15.4 M
Pretty Stable
Reconciled Depreciation1.9 K2 K941.2 K
Slightly volatile
Cost Of Revenue5.8 M5.5 M1.7 M
Slightly volatile
Non Operating Income Net Other423.2 K476.1 K519.1 K
Slightly volatile

Alaunos Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow5.8 M6.1 M65 M
Pretty Stable
Depreciation1.9 K2 K821.9 K
Slightly volatile
End Period Cash Flow1 M1.1 M61 M
Slightly volatile
Stock Based Compensation413.2 K435 K5 M
Very volatile
Dividends Paid13.3 M19.5 M12.6 M
Slightly volatile
Change To Netincome6 K6.3 K10.7 M
Pretty Stable
Change Receivables885.6 K996.3 K1.1 M
Slightly volatile
Cash Flows Other Operating3.4 M3.9 M4.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio291306739
Very volatile
Dividend Yield0.02940.0570.0376
Slightly volatile
Days Sales Outstanding110164303
Slightly volatile
Average Payables465.9 K725.5 K751.8 K
Very volatile
Stock Based Compensation To Revenue41.1139.1517.7746
Slightly volatile
Capex To Depreciation0.07280.07661.5148
Pretty Stable
EV To Sales187197576
Very volatile
Inventory Turnover0.160.180.1945
Slightly volatile
Days Of Inventory On Hand1.5 K1.7 K1.8 K
Slightly volatile
Payables Turnover7.377.022.052
Slightly volatile
Sales General And Administrative To Revenue2.3 K2.2 K463
Slightly volatile
Research And Ddevelopement To Revenue34.3936.2272
Slightly volatile
Capex To Revenue37.2335.469.0473
Slightly volatile
Cash Per Share0.650.681375.2146
Slightly volatile
Days Payables Outstanding51.1453.83411
Slightly volatile
Income Quality0.581.06240.7154
Pretty Stable
Intangibles To Total Assets0.520.870.896
Very volatile
Current Ratio4.823.98125.58
Very volatile
Receivables Turnover690657220
Slightly volatile
Capex Per Share0.130.141.179
Very volatile
Average Receivables186209228
Slightly volatile
Revenue Per Share0.00590.00621.9204
Slightly volatile
Interest Debt Per Share1.311.383.7192
Slightly volatile
Debt To Assets0.570.360.2499
Pretty Stable
Operating Cycle244164426
Slightly volatile
Days Of Payables Outstanding51.1453.83411
Slightly volatile
Quick Ratio4.813.98125.5433
Very volatile
Net Income Per E B T1.231.151.3399
Slightly volatile
Cash Ratio1.51.57664.5248
Slightly volatile
Days Of Inventory Outstanding1.5 K1.7 K1.8 K
Slightly volatile
Days Of Sales Outstanding110164303
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.860.913.5833
Pretty Stable
Fixed Asset Turnover2.842.882.1708
Very volatile
Debt Ratio0.570.360.2499
Pretty Stable
Price Sales Ratio291306739
Very volatile
Asset Turnover0.00340.00360.0547
Slightly volatile

Alaunos Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.9 M3.1 M377.7 M
Slightly volatile
Enterprise Value1.9 M2 M316.5 M
Slightly volatile

Alaunos Fundamental Market Drivers

Alaunos Upcoming Events

5th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
5th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Alaunos Therapeutics Financial Statements

Alaunos Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Alaunos Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Alaunos Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Alaunos Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue14.9 K14.2 K
Total Revenue10 K9.5 K
Cost Of Revenue5.5 M5.8 M
Stock Based Compensation To Revenue 39.15  41.11 
Sales General And Administrative To Revenue2.2 K2.3 K
Research And Ddevelopement To Revenue 36.20  34.39 
Capex To Revenue 35.46  37.23 
Revenue Per Share 0.01  0.01 
Ebit Per Revenue(481.20)(505.26)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Alaunos Stock Analysis

When running Alaunos Therapeutics' price analysis, check to measure Alaunos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alaunos Therapeutics is operating at the current time. Most of Alaunos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Alaunos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alaunos Therapeutics' price. Additionally, you may evaluate how the addition of Alaunos Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY